Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Adult | US | 2024

Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs]) that are often effective for those patients with mild to moderate disease. Treatment then progresses to more-potent drugs, such as immunosuppressants and/or biologics, as needed. Among the biologics, tumor necrosis factor (TNF)-alpha inhibitors (Janssen’s Remicade and AbbVie’s Humira), a cell adhesion molecule (CAM) inhibitor (Takeda’s Entyvio), and an IL-12/23 inhibitor (Janssen’s Stelara) are the mainstays of treatment, followed by oral targeted therapies comprising Janus kinase (JAK) inhibitors (Pfizer’s Xeljanz / Xeljanz XR and AbbVie’s Rinvoq). However, later-to-market drugs, such as a sphingosine 1-phosphate receptor (S1P-R) modulators (BMS’s Zeposia and Pfizer’s Velsipity) and an IL-23 inhibitor (Eli Lilly’s Omvoh), are increasing the market competition among later-line targeted therapies. Moreover, the availability of infliximab biosimilars and adalimumab biosimilars in the United States will further impact market dynamics.

For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult UC patients?
• How have Rinvoq and Omvoh been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of adult UC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of adult UC patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: AbbVie, Janssen, Pfizer, Takeda, UCB, BMS

Key drugs: Humira, Remicade, biosimilar infliximab, Entyvio, Stelara, Xeljanz / Xeljanz XR, Simponi, Zeposia, Rinvoq, aminosalicylates, immunosuppressants

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses